AEterna Zentaris subsidiary, Atrium Biotechnologies, acquires Douglas Laboratories in the U.S.

AEterna Zentaris subsidiary, Atrium Biotechnologies, acquires Douglas Laboratories in the U.S. Atrium Biotechnologies Inc. has acquired HVL Inc., whose main brand is Douglas Laboratories for the total amount of $107 million ($US 92 million), approximately 6.4 times the adjusted EBITDA generated by Douglas.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Industry Coalition Advises Against Use of Dietary Supplements as Remedy for Avian Flu The trade associations of the dietary supplement industry urge industry to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu, refrain from promoting any dietary supplement as a preventative, cure or treatment for avian flu, and arge those who believe they may have avian flu or may have come in contact with it should immediately contact a healthcare professional. Industry Coalition Advises Against Use of Dietary Supplements as Remedy for Avian Flu The trade associations of the dietary supplement industry urge industry to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu, refrain from promoting any dietary supplement as a preventative, cure or treatment for avian flu, and arge those who believe they may have avian flu or may have come in contact with it should immediately contact a healthcare professional. Jarrow Formulas® Donates 20,000 Bottles of Product to The Vitamin Angel Alliance for Hurricane and Earthquake Victims Jarrow Formulas®, Inc. has donated 20,000 bottles of vitamins – 10,000 each of its Women’s Multi and Kid’s Multi – to the Vitamin Angel Alliance for victims of the recent hurricanes and earthquake. Jarrow Formulas® Donates 20,000 Bottles of Product to The Vitamin Angel Alliance for Hurricane and Earthquake Victims Jarrow Formulas®, Inc. has donated 20,000 bottles of vitamins – 10,000 each of its Women’s Multi and Kid’s Multi – to the Vitamin Angel Alliance for victims of the recent hurricanes and earthquake. Jarrow Formulas® Donates 20,000 Bottles of Product to The Vitamin Angel Alliance for Hurricane and Earthquake Victims Jarrow Formulas®, Inc. has donated 20,000 bottles of vitamins – 10,000 each of its Women’s Multi and Kid’s Multi – to the Vitamin Angel Alliance for victims of the recent hurricanes and earthquake. New Scholarship to Honor the Late Dr. Khem Shahani A newly established professorship at the University of Nebraska-Lincoln (UNL) honors the life of scientist and professor Khem M. Shahani while helping to continue his acclaimed research in healthy food bacteria. New Scholarship to Honor the Late Dr. Khem Shahani A newly established professorship at the University of Nebraska-Lincoln (UNL) honors the life of scientist and professor Khem M. Shahani while helping to continue his acclaimed research in healthy food bacteria. New Scholarship to Honor the Late Dr. Khem Shahani A newly established professorship at the University of Nebraska-Lincoln (UNL) honors the life of scientist and professor Khem M. Shahani while helping to continue his acclaimed research in healthy food bacteria. Solbar Restructures for New Challenges Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division. Solbar Restructures for New Challenges Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division. Solbar Restructures for New Challenges Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division. Solbar Restructures for New Challenges Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division. Solbar Restructures for New Challenges Company restructures into two divisions with Assaf Gadish assuming responsibilities for the Commodities Soy division and Gidi Landsberger to lead Solbar's Specialty Products Division. FSANZ Invites Comment About Draft Health Claims Standard Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition. FSANZ Invites Comment About Draft Health Claims Standard Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition. FSANZ Invites Comment About Draft Health Claims Standard Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition. FSANZ Invites Comment About Draft Health Claims Standard Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition. FSANZ Invites Comment About Draft Health Claims Standard Proposed standard has two levels of claims - general claims aboub content or general health about a non-serious disease, and then hig-level health claims in relation to a serious disease or condition. Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure. Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure. Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure. Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure. Jarrow Formulas, Inc. Unveils Pressure Optimizer(TM), With AmealPeptide(TM), a Patented Extract of Hydrolyzed Casein Company announces the introduction of Pressure Optimizer(TM), with primary constituent is AmealPeptide(TM), a patented extract of hydrolyzed casein that contains two tripeptides (Valyl-Prolyl-Proline, Isoleucyl-Prolyl-Proline) extensively clinically studied for their effect on blood pressure. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Database for New Dietary Ingredient Notifications Launches The American Herbal Products Association (AHPA) and NPIcenter have collaborated to create a database for accessing all of the notifications that FDA has received since 1994 for new dietary ingredients (NDIs). The AHPA NDI Database launched on Monday, December 5, 2005, with a one-day-only open access trial period, before the subscription period began. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Study Finds Omega-3 Fatty Acids Help Decrease Postpartum Depression randomized dose-ranging pilot trial of Omega-3 fatty acids for post-partum depression indicates that scores on depression measures decreased by approximately 50 percent, and were statistically significant. Health Wright Products Announces Major Expansion Company announces the acquisition and development of a new 120,350 square foot facility in Clackamas, OR; new facility is expected to be completed and fully functional in early 2006. Health Wright Products Announces Major Expansion Company announces the acquisition and development of a new 120,350 square foot facility in Clackamas, OR; new facility is expected to be completed and fully functional in early 2006. Health Wright Products Announces Major Expansion Company announces the acquisition and development of a new 120,350 square foot facility in Clackamas, OR; new facility is expected to be completed and fully functional in early 2006. Hyperforin Plasma Level Inconsistency Found in 2002 St. John’s Wort Study An article that was quietly presented in a medical journal last summer reported significant disparities in hyperforin plasma levels in many of the participants in a study on St. John’s wort (Hypericum perforatum) and major depression that had been published in the Journal of the American Medical Association (JAMA) over 3 years earlier. Hyperforin Plasma Level Inconsistency Found in 2002 St. John’s Wort Study An article that was quietly presented in a medical journal last summer reported significant disparities in hyperforin plasma levels in many of the participants in a study on St. John’s wort (Hypericum perforatum) and major depression that had been published in the Journal of the American Medical Association (JAMA) over 3 years earlier. Hyperforin Plasma Level Inconsistency Found in 2002 St. John’s Wort Study An article that was quietly presented in a medical journal last summer reported significant disparities in hyperforin plasma levels in many of the participants in a study on St. John’s wort (Hypericum perforatum) and major depression that had been published in the Journal of the American Medical Association (JAMA) over 3 years earlier. 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada. 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada. 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada. 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada. 3rd Natural Health Product Research Conference: From Concept to Consumer- March 3 – 5, 2006 - Toronto, Canada Subtitled 'From Concept to Consumer' this annual conference is the premiere NHP scientific event in North America, showcasing the year’s best original research and providing a critically needed forum for dialogue amongst NHP research stakeholders. It will be held March 3 – 5, 2006 in Toronto, Ontario, Canada. Celanese Has Sold Its omega-3 DHA Business to Lonza Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed. Celanese Has Sold Its omega-3 DHA Business to Lonza Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed. Celanese Has Sold Its omega-3 DHA Business to Lonza Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed. Celanese Has Sold Its omega-3 DHA Business to Lonza Company has sold the omega-3 DHA business of its performance products segment Nutrinova to Lonza Ltd., Switzerland. Financial details of the deal were not disclosed. ORAFTI’s Synergy 1® Receives Natural Products Award Orafti Active Food Ingredients has announced that its proprietary enriched inulin ingredient Synergy 1® has been honored as Editors’ Choice in Nutritional Outlook Magazine’s 2005 Natural Products Awards. ORAFTI’s Synergy 1® Receives Natural Products Award Orafti Active Food Ingredients has announced that its proprietary enriched inulin ingredient Synergy 1® has been honored as Editors’ Choice in Nutritional Outlook Magazine’s 2005 Natural Products Awards. ORAFTI’s Synergy 1® Receives Natural Products Award Orafti Active Food Ingredients has announced that its proprietary enriched inulin ingredient Synergy 1® has been honored as Editors’ Choice in Nutritional Outlook Magazine’s 2005 Natural Products Awards. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. EuroPharma® Selected As Exclusive Research And Development Team for Chicken Soup for the Soul(TM) Supplements EuroPharma’s president Terry Lemerond has developed an exclusive line of supplements for the Chicken Soup for the Soul® brand to be marketed through a network of independent sales affiliates and direct response radio and TV advertising. Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). Bonkers(TM) Performance Teas Introduces Brain Boost With SerinAid® & Bacopa And Maximum Performance Super Energizer With AlphaSize® & Guarana Company introduces mental performance enhancing teas that deliver useful amounts of both phosphatidylserine (PS) and alpha-glyceryl phosphoryl choline (A-GPC). IdeaSphere Obtains Exclusive Worldwide License to Weil Nutritional Supplements Company announces that it has reached an agreement in principle with Weil Lifestyle to assume exclusive, worldwide licensing rights to Weil Nutritional Supplements (exclusing Canada). IdeaSphere Obtains Exclusive Worldwide License to Weil Nutritional Supplements Company announces that it has reached an agreement in principle with Weil Lifestyle to assume exclusive, worldwide licensing rights to Weil Nutritional Supplements (exclusing Canada). Chr. Hansen Launches New Animal Health and Nutrition Website Chr. Hansen has announced an updated animal health and nutrition website which encompasses Chr. Hansen's total product offering for the agricultural industry - including former Medipharm solutions. Chr. Hansen Launches New Animal Health and Nutrition Website Chr. Hansen has announced an updated animal health and nutrition website which encompasses Chr. Hansen's total product offering for the agricultural industry - including former Medipharm solutions. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. Natural Remedies Launches GutGard™ Web Site Natural Remedies has announced the launch of its new branded ingredient web site for GutGard. General Nutrition Centers, Inc. Reports FY09 Q3 Results General Nutrition Centers, Inc., has announced their FY09 Q3 results, reporting consolidated revenues of $430.8 million, an increase of 4.0% over the consolidated revenues of $414.2 million for the same quarter of 2008. General Nutrition Centers, Inc. Reports FY09 Q3 Results General Nutrition Centers, Inc., has announced their FY09 Q3 results, reporting consolidated revenues of $430.8 million, an increase of 4.0% over the consolidated revenues of $414.2 million for the same quarter of 2008. General Nutrition Centers, Inc. Reports FY09 Q3 Results General Nutrition Centers, Inc., has announced their FY09 Q3 results, reporting consolidated revenues of $430.8 million, an increase of 4.0% over the consolidated revenues of $414.2 million for the same quarter of 2008. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health Bayer Consumer Care has announced the launch of their new Citracal(R) Calcium plus Heart Health for bone and heart care. Senomyx Announces Corporate Update and FY09 Q3 Results Senomyx, Inc., has announced their FY09 Q3 results, reporting revenues were $4.2 million for the third quarter of 2009, compared to $4.0 million for the third quarter of 2008, an increase of 3%. Senomyx Announces Corporate Update and FY09 Q3 Results Senomyx, Inc., has announced their FY09 Q3 results, reporting revenues were $4.2 million for the third quarter of 2009, compared to $4.0 million for the third quarter of 2008, an increase of 3%. Senomyx Announces Corporate Update and FY09 Q3 Results Senomyx, Inc., has announced their FY09 Q3 results, reporting revenues were $4.2 million for the third quarter of 2009, compared to $4.0 million for the third quarter of 2008, an increase of 3%. GLG Life Tech Corporation Announces Receipt of Demand Letter GLG Life Tech Corporation has announced that it has received a demand letter from Weider Global Nutrition that states that WGN will commence, on November 4, 2009, legal proceedings in the Supreme Court of British Columbia against the Company. GLG Life Tech Corporation Announces Receipt of Demand Letter GLG Life Tech Corporation has announced that it has received a demand letter from Weider Global Nutrition that states that WGN will commence, on November 4, 2009, legal proceedings in the Supreme Court of British Columbia against the Company. GLG Life Tech Corporation Announces Receipt of Demand Letter GLG Life Tech Corporation has announced that it has received a demand letter from Weider Global Nutrition that states that WGN will commence, on November 4, 2009, legal proceedings in the Supreme Court of British Columbia against the Company. GLG Life Tech Corporation Announces Receipt of Demand Letter GLG Life Tech Corporation has announced that it has received a demand letter from Weider Global Nutrition that states that WGN will commence, on November 4, 2009, legal proceedings in the Supreme Court of British Columbia against the Company. GLG Life Tech Corporation Announces Receipt of Demand Letter GLG Life Tech Corporation has announced that it has received a demand letter from Weider Global Nutrition that states that WGN will commence, on November 4, 2009, legal proceedings in the Supreme Court of British Columbia against the Company. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits. Ingredients Manufacturer Goes Small Taura Natural Ingredients has announced their new Mini Fruit Bits.	QUEBEC CITY, Dec 08, 2005 /PRNewswire-FirstCall via COMTEX/ -- AEterna Zentaris Inc. (CA:AEZ)(AEZS) is pleased to announce that its subsidiary, Atrium Biotechnologies Inc. ("Atrium" TSX: ATB.sv), has acquired, effective today, Pittsburgh-based HVL Inc. ("Douglas") whose main brand is Douglas Laboratories. Douglas has been marketing health and nutritional products through healthcare practitioners for over 50 years and has current annual revenues of approximately $80 million. By acquiring Douglas, Atrium now positions itself as the leader in this sector throughout the United States. The transaction is immediately accretive to Atrium, enabling it to increase its adjusted earnings before interest, income taxes, depreciation and amortization (EBITDA) from approximately $31 million to about $48 million on a pro forma basis and therefore also increasing its earnings per share by more than 50%, before synergies. Following the transaction, Atrium's pro forma revenues will exceed $315 million. Under the agreement, Atrium will acquire Douglas for the total amount of $107 million ($US 92 million), which represents approximately 6.4 times the adjusted EBITDA generated by Douglas. Approximately $97 million will be paid in cash while the remainder, approximately $10 million, will be paid in Atrium subordinate voting shares issued to certain Douglas management shareholders at a price of $10.95 per share. The cash portion will come from Atrium's cash on hand and its newly re-negotiated credit facility that can be increased to $200 million, under certain conditions. "This significant acquisition represents Atrium's commitment to its aggressive corporate development strategy as well as immediately increases its EBITDA, net earnings and net earnings per share," stated Gilles Gagnon, President and Chief Executive Officer at AEterna Zentaris. Atrium Biotechnologies has issued a detailed press release on this transaction which is available on its Website at www.atrium-bio.com and also on SEDAR. About Atrium Atrium Biotechnologies Inc. is a leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. Atrium focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America, Europe and Asia. Additional information about Atrium is available on its Web site at www.atrium-bio.com. About HVL / Douglas Founded in 1955, Douglas directly markets some 960 products to approximately 10,000 healthcare practitioners, such as physicians, chiropractors and osteopaths. The Company also sells supplements via distributors that work with health professionals. Douglas, which has approximately 250 employees, markets its products under various well-known brand names, including Douglas Laboratories, Advanced Medical Nutrition Incorporated (AMNI), Health Yourself and Intelligent Health. In addition to manufacturing and marketing its own exclusive brand name supplements, which make up the majority of its business, Douglas also designs and manufactures products for others in the industry. It has a 150,000 square-foot plant in Pittsburgh regrouping production facilities, warehouse facilities, laboratories and its head office. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a growing global biopharmaceutical company engaged in the discovery, development and marketing of therapies for cancer and endocrine disorders. AEterna Zentaris also owns 48.5% of the equity of Atrium Biotechnologies Inc. (CA:ATBSV) and 64.9 % of its voting rights. Atrium is a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries. News releases and additional information are available at www.aeternazentaris.com. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software